PATENT CLAIM ANALYSIS

Application Number: 16308908
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-05
Patent Classification: ["424", "465000"]

Abstract:
The present invention relates to a stable pharmaceutical formulation of solid dosage forms for oral administration comprising a therapeutically effective amount of a non-purine selective inhibitor of xanthine oxidase, in particular Febuxostat and an effective amount of an alkalizing agent. It also relates to a process for the preparation thereof.

Claim (Index 9):
The process according to  claim 8  comprising Febuxostat polymorphic form C with particle size distribution of {umlaut over (\u03c5)}90<30 \u03bcm.

Metadata:
- Claim Count in Document: 16.0
- Percentile: 98.0
- Lexical Diversity: 1.325
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['13160572', '15010212', '12739475', '14006032', '13990632']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6924929778815632
- 35 USC 102 Novelty (BERT): 0.4973977203796038
- Combined Prediction Score: 0.6729834521313673
- Mean Citation Score: 167.35468000000003
- Max Citation Score: 190.09056
- Similarity Product: 117.65816278839114

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test